Council Of Scientific And Industrial Research Collaborates With Aurobindo Pharma To Develop COVID-19 Vaccines

Hyderabad: The Council of Scientific and Industrial Research (CSIR) and Aurobindo Pharma Limited on Tuesday (September 15) announced a collaboration to develop vaccines for COVID-19. As per the release issued by the Centre for Cellular & Molecular Biology (CCMB), under the signed agreement between CSIR- CCMB and Aurobindo Pharma, Aurobindo will partner with CSIR for the development of several novel COVID-19 vaccines.

Also Read: Russia To Supply 100 Million Doses Of COVID-19 Vaccine To India’s Dr. Reddy’s Laboratories

“Three CSIR labs namely CCMB Hyderabad, Institute of Medical Technology (IMTECH), Chandigarh and Indian Institute of Chemical Biology (IICB), Kolkata are developing vaccine candidates using different technology platforms. Aurobindo will undertake clinical development and commercialization of the vaccines,” it said.

Commenting on this partnership, Dr Shekhar C Mande, Director General, CSIR, said that

Joining of hands of premier CSIR labs with industry for the development of vaccines will amplify India’s efforts in indigenous vaccine development and also help in preparedness for future pandemics.

Dr. Rakesh Mishra, Director, CSIR-CCMB, while talking about the development strategies for the vaccines said,

Our labs are working on novel proteins for vaccine development that has the potential to address the need for a second-generation vaccine. We are happy to partner with Aurobindo who have proven manufacturing and commercialization capabilities.

Also Read: Coronavirus Vaccine Updates: What Is A Human Challenge Trial And Can It Speed Up COVID-19 Vaccine Development?

Aurobindo Pharma Limited also expresses pride over the collaboration with CSIR for developing vaccines to combat the COVID-19 pandemic and said that is already setting up a large-scale facility in Hyderabad for manufacturing the vaccine.

We are proud to join hands with CSIR for developing vaccines to combat the COVID-19 pandemic. This collaboration further strengthens our COVID-19 vaccine development efforts. We are already setting up a large-scale facility in Hyderabad for manufacturing COVID-19 vaccine and other viral vaccines, said N. Govindarajan, Managing Director, Aurobindo Pharma Limited.

Also Read: ‘Excellent Safety’ Of Two Indigenous COVID Candidate Vaccines Revealed During Phase-I Trials: Minister

The release said that apart from this collaboration, Aurobindo is already developing a vaccine for COVID-19 (SARS COV-2) through its wholly-owned US subsidiary Auro Vaccines.

The SARS COV-2 vaccine candidate is based on the company’s proprietary replication-competent, attenuated, recombinant vesicular stomatitis (VSV, VesiculoVax(tm)) vaccine delivery platform, it added.

Also Read: Three COVID-19 Vaccines At Clinical Trial Stage In India: Indian Council of Medical Research

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.) 

NDTV – Dettol Banega Swasth India campaign is an extension of the five-year-old Banega Swachh India initiative helmed by Campaign Ambassador Amitabh Bachchan. It aims to spread awareness about critical health issues facing the country. In wake of the current COVID-19 pandemic, the need for WASH (Water, Sanitation and Hygiene) is reaffirmed as handwashing is one of the ways to prevent Coronavirus infection and other diseases. The campaign highlights the importance of nutrition and healthcare for women and children to prevent maternal and child mortality, fight malnutrition, stunting, wasting, anaemia and disease prevention through vaccines. Importance of programmes like Public Distribution System (PDS), Mid-day Meal Scheme, POSHAN Abhiyan and the role of Aganwadis and ASHA workers are also covered. Only a Swachh or clean India where toilets are used and open defecation free (ODF) status achieved as part of the Swachh Bharat Abhiyan launched by Prime Minister Narendra Modi in 2014, can eradicate diseases like diahorrea and become a Swasth or healthy India. The campaign will continue to cover issues like air pollution, waste management, plastic ban, manual scavenging and sanitation workers and menstrual hygiene.  

[corona_data_new]